Crocodile Capital Partners’s BioNTech BNTX Stock Holding History

Crocodile Capital Partners’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.75M	Hold	29,586	–	–	1.87%	6
2026 Q1	$2.82M	Hold	29,586	–	–	2.02%	7
2025 Q4	$2.82M	Hold	29,586	–	–	1.68%	9
2025 Q3	$2.92M	Hold	29,586	–	–	2.38%	5
2025 Q2	$3.15M	Hold	29,586	–	–	5.29%	4
2025 Q1	$2.69M	Hold	29,586	–	–	3.81%	5
2024 Q4	$3.37M	Hold	29,586	–	–	9.39%	3
2024 Q3	$3.51M	Hold	29,586	–	–	4.96%	6
2024 Q2	$2.38M	Hold	29,586	–	–	3.78%	6
2024 Q1	$2.73M	Hold	29,586	–	–	3.76%	6
2023 Q4	$3.12M	Hold	29,586	–	–	3.71%	6
2023 Q3	$3.21M	Hold	29,586	–	–	3.03%	4
2023 Q2	$3.19M	Buy	+29,586	New	+$3.33M	3.26%	5

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Crocodile Capital Partners's BNTX Position: Q2 2026 in Review

Crocodile Capital Partners held its BioNTech (BNTX) position steady in Q2 2026 at 29,586 shares worth $2.75M. The position accounts for 1.87% of the portfolio, ranked #6.

Crocodile Capital Partners first reported a position in BNTX in Q2 2023 and has held it in 13 quarters since. The position peaked at $3.51M in Q3 2024. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Crocodile Capital Partners held 29,586 shares of BioNTech worth $2.75M as of Q2 2026.
Crocodile Capital Partners left its BioNTech share count unchanged in Q2 2026.
BioNTech made up 1.87% of Crocodile Capital Partners's portfolio in Q2 2026, its #6 holding.
Crocodile Capital Partners first reported a position in BioNTech in Q2 2023 and has held it in 13 quarters since.
Crocodile Capital Partners's BioNTech position peaked at $3.51M in Q3 2024.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Crocodile Capital Partners's 13F filing for Q2 2026, filed 7 Jul 2026.